Steve is the Chief Executive Officer at EmbarkNeuro. Steve is a Neuropsychiatrist with a career in basic neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years. Prior to joining Ancora he was Chief Medical Officer of Sage Therapeutics, where he led the successful clinical development of ZULRESSO® (brexanolone), the first-ever treatment approved for Postpartum Depression (PPD), along with the buildout of the development organization and Sage Therapeutics’ broad neuroscience portfolio. Earlier in his career, Steve was Executive Director in Clinical Development in the Inflammation, Neuroscience and Respiratory therapeutic areas at AstraZeneca, and a faculty member of the University of Pennsylvania Department of Psychiatry. In addition to his role at EmbarkNeuro, Steve is currently a member of the Board of Directors of Verge Genomics.
Steve received both his PhD in Molecular and Cellular Pharmacology and his MD from the Stony Brook University Renaissance School of Medicine and completed his residency training in the Yale University School of Medicine Department of Psychiatry.
Mark Fishman is a Co-Founder and Chair of the Scientific Advisory Board at Aditum Bio. Prior to this, Mark was the Founding President at the Novartis Institutes for Biomedical Research (NIBR) (2002-2016). Mark is currently a Professor of Stem Cell and Regenerative Biology at Harvard. During his tenure, NIBR discovered and brought through successful early clinical trials 90 new medicines in more than 120 indications. Prior to Novartis, while Chief of Cardiology and Director of the Cardiovascular Research Center at Harvard Medical School and the MGH, Dr. Fishman’s research helped to introduce the zebrafish as a genetic model organism.
Dr. Fishman is a member of the National Academy of Medicine and a fellow of the American Academy of Arts and Sciences. In addition to his publications in developmental biology and drug discovery, Dr. Fishman is the author of the textbook ‘Medicine’ and the textbook ‘Lab’, an architecture book on how to design buildings for scientists.
Dr. Fishman graduated from Yale College and Harvard Medical School and trained in medicine and cardiology at the MGH.
Joe Jimenez is a Co-Founder and Managing Director at Aditum Bio. Joe is the Former Chief Executive Officer of Novartis, one of the world’s leading pharmaceutical companies. Under his leadership, Novartis developed one of the largest pipelines of self-originated drugs in the industry.
Prior to his role as CEO, Joe served as the Division Head for both Novartis Pharmaceuticals and Novartis Consumer Health. Joe is currently a member of the Board of Directors of Procter & Gamble and General Motors.
Chris Klee has 30 years of pharmaceutical industry experience in finance. He has held multiple roles within the Novartis organization. In 2005, Mr. Klee joined the Novartis Institutes for BioMedical Research (NIBR) as Chief Financial Officer and later assumed an expanded role as CFO & Chief Operating Officer. During his tenure at NIBR, he served on boards of several biotech companies. Mr. Klee was the CFO of Novartis USA (2016-2021) before he joined Aditum Bio.
Chris graduated from the Business School of the University of St. Gallen in Switzerland with a degree in Finance and Economics.